“Explore Your Treatment Options,” a new multimedia ad campaign announced today by the U.S. Department of Health and Human Services’ Agency for Healthcare Research and Quality (AHRQ) and the Ad Council, encourages patients to become more informed about their options before choosing a treatment for a health condition or illness.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/adcouncil/50583/
Nearly five black women die needlessly per day from breast cancer in the United States – a total of 1,722 deaths annually – according to a study released today at the Avon Foundation Breast Cancer Forum and simultaneously published in Cancer Epidemiology. The 2012 Racial Disparity in Breast Cancer Mortality Study found that 21 of the 25* largest U.S. cities have a black: white disparity in breast cancer mortality, 13 of which are statistically significant.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52895-avon-foundation-breast-cancer-forum-racial-disparity-mortality-study
ORBIS is excited to announce the return of its Flying Eye Hospital (FEH) to EAA AirVenture at Wittman Regional Airport in Oshkosh, Wisconsin. This is the first time since 2003 that the aircraft has been featured at the airshow – the largest gathering of aviation enthusiasts in the United States. ORBIS will be opening the aircraft’s doors at this year’s airshow, giving visitors the opportunity to tour the world’s only airborne ophthalmic training facility in the world. Today, ORBIS will announce details of its new FEH – a MD-10 aircraft that is currently undergoing transformation from a cargo plane into the next generation Flying Eye Hospital.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51620-orbis-flying-eye-hospital-airventure-oshkosh-airshow
Computerized tomographic (CT) colonography (CTC), also known as virtual colonoscopy, is comparable to standard colonoscopy in its ability to accurately detect cancer and precancerous polyps in people ages 65 and older, according to a paper published online today in Radiology. This is consistent with results of the ACRIN National CT Colonography Trial, published in the New England Journal of Medicine in 2008, which demonstrated that CT colonography can serve as a primary colorectal cancer screening option for adults ages 50 and older, but did not specifically break out data for participants ages 65 and older included in the overall analysis. The Centers for Medicare and Medicaid Services have deferred coverage for CT colonography, primarily citing a lack of data on the exam’s performance in Medicare-eligible recipients ages 65 and older.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54777-acrin-national-ct-colonography-study-radiology-cancer-screening-seniors
As the NCAA college basketball tournament approaches, the National Center for Responsible Gaming (NCRG) is launching a public awareness initiative to encourage college administrators, campus health professionals and students to learn more about college gambling and gambling-related harms. The campaign also helps to educate students who are of legal age about how to make responsible decisions about gambling.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54256-ncrg-resource-educates-universities-and-students-about-college-gambling
Today the International OCD Foundation (IOCDF), announced their support for children and families suffering from Sudden Onset Obsessive Compulsive Disorder. They are releasing two new PSAs created to bring awareness and engender change surrounding the disorder PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections) and PANS (Pediatric Acute-Onset Neuropsychiatric Syndrome).
To view Multimedia News Release, go to http://www.multivu.com/mnr/54781-ocd-foundation-pandas-psa-obsessive-compulsive-disorder
Children’s Memorial Hermann Hospital and Cord Blood Registry® (CBR) are launching the first FDA-approved, Phase I safety study on the use of cord blood stem cells to treat children with sensorineural hearing loss.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53686-cord-blood-childrens-memorial-hermann-fda-approved-stem-cells-hearing-loss
Under the leadership of the National Organization for Rare Disorders (NORD), the primary organization in the U.S. representing people with rare diseases, millions of Americans will gather tomorrow to observe the 5th annual Rare Disease Day. This international observance unites people around the globe to focus attention on the estimated 300 to 350 million patients worldwide afflicted with rare diseases and to recognize that their needs are a global public health concern. In the U.S., a rare disease is one that affects fewer than 200,000 Americans.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60507-nord-rare-disease-day
Conoce las Preguntas, una nueva campaña de multimedia en español, anunciada hoy por la Agency for Healthcare Research and Quality (Agencia para la Investigación y Calidad de los Servicios de Salud
Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced that its epilepsy-focused educational website, http://www.Epilog.us, has been expanded to include thought-leader commentary on issues related to Epilepsy and Comorbidities. The newly updated website will make its debut at the 64th Annual American Academy of Neurology Meeting in New Orleans on April 23 – 26, 2012, at the Upsher-Smith exhibit, booth number 128.
TO view Multimedia News Release, go to http://www.multivu.com/mnr/55934-upsher-smith-expands-epilog-us-on-epilepsy-comorbidities
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.
The data showed that treatment with SAR236553/REGN727 over 8 to 12 weeks significantly reduced mean low-density lipoprotein-cholesterol (LDL-C, or “bad” cholesterol) by 40% to 72% in patients with elevated LDL-C on stable dose of statins.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55299-sanofi-regeneron-pharmaceuticals-lipid-lowering-medications-pcsk9-antibody
As the most trusted name in sexual health for more than 90 years, the makers of Trojan® Brand Condoms remain dedicated to dispelling the myths and misinformation surrounding condoms and reinforcing condom efficacy and ease of use through proven facts and education. The makers of Trojan® Brand Condoms have partnered with renowned sexual health experts and organizations like the American Social Health Association (ASHA) to develop tools that provide consumers with the accurate information they need to make responsible decisions about their sex life.
To view Multimedia News Release, go to http://www.multivu.com/players/English/54610-trojan-condoms
